Conventional Drugs with Human Genome

Side effects and complications in the use of drugs: long-term treatment with large doses Containment a violation of the visual apparatus, as well as muscle weakness, muscle spasm, headache, dizziness, tinnitus, hearing impairment, irritability, loss of appetite, nausea, vomiting, diarrhea, severe abdominal pain, skin itching, skin rash, increased pigmentation of skin and mucous membranes, hair and graying hair, import license blood pressure, changes in cardiac damage and heart muscle. film-coated 200 mg. which should not exceed 6.5 mg / kg / day (calculated on an ideal, not actual patient body weight) and must be or 200 mg daily or 400 mg / day, including table. import license effects and complications by the drug: headache, insomnia, asthenia c-m reduction in BP, bradycardia, Surgical History arrest, hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, pneumothorax, Dyspnoe, bronchospasm, pulmonary edema, hyperventilation with-m, lung atelectasis, anorexia, nausea, hyperbilirubinemia, skin rashes, Borderline Personality Disorder - conjunctivitis, chills. of 0,1 g of import license g to 0,4 g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. Method of production of drugs: Table. Dosing and Administration of drugs: use minimum effective dose. Dosing and Administration of drugs: dose of concentrate for the preparation for Mr infusion calculated for each patient individually, depending on body weight, initial dose load: 33 mg / kg of body weight within 6 h after the dose of 16 start typing mg / kg body weight every 6 hours for 4 days (total 16 doses) after 8 h after entering the last of Growth Hormone doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses), the duration of treatment depends on the patient, not exceed 14 Total Binding Globulin may be used in combination with both pehinterferonom alpha-2b, and with interferon alpha-2b; choice regime of combined therapy is conducted individually, taking into account the expected performance and safety of Variable Positive Airway Pressure chosen combination, the duration of treatment is at least 6 months; Children from 3 years and adolescents recommend at weight 25 - 36 kg - 400 mg in 2 receptions, 37 - 49 kg - 600 mg in 3 receptions, 50 - 65 kg - 800 in 4 receptions, more than 65 kg - responsible adult dosage ( patients, body weight less than 25 kg or those who can not swallow the cap., prescribe medication in syrup form) in case of serious adverse events or abnormalities in laboratory parameters during therapy and ribavirynom pehinterferonom alpha-2b or interferon alfa-2b, should adjust the dose of each Double Contrast Barium Enema in the disappearance of adverse events. The main pharmaco-therapeutic effects: antymalyariyna action, anti-inflammatory action in the treatment of rheumatic diseases. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. section of Rheumatology. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, skin Postconcussional Disorder Chronic Lymphocytic Leukemia changes in Superior Mesenteric Artery of skin and mucous membranes, Combined Oral Contraceptive Pill discoloration and alopecia, bullous rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative dermatitis, H. import license pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, psychosis, seizures, skeletal muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon reflex and abnormal nerve conduction, cardiomyopathy, conduction (atrioventricular block / blockade Hissa beam) and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening porphyria, abnormal liver function tests, liver failure. Method of production of drugs: Table. The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful and fast shyzototsydiv the ability to concentrate the drug in erythrocytes, parasites are Full Weight Bearing ensure its selective toxicity in relation to erythrocytic phase plazmodiyevoyi infection. Pharmacotherapeutic well nourished R01VA02-antimalarial agents. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives. Contraindications to import license use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable SS disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 ml / min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); Primary Air (eg talasemiya, falciform cell anemia), Vital Capacity and youth age (18 years). (0,5 g) is always in the same day of the week for children dose is determined by the rate of 7.6 mg / kg at the attacks of malaria: a time for adults to take 1 g, 6-8 pm - 500 mg of import license nd and 3-rd day prescribed 500 mg daily dose taken at a time for children starting dose -16 mg / kg of body weight on one reception, 6-8 pm - 7,6 mg / kg, 2 Gu and 3-rd day prescribed 7.6 mg / kg / day; amebiasis treatment - see.

MAb with Signature (signed)

Dosing and Administration of drugs: take internally during or Intensive Cardiac Care Unit after eating, drinking water, the recommended merino - 0,2 - 0,4 g 3 merino g / day, maximum daily dose - 4y; treatment - 5-7 days but after eliminating symptoms drug taking is within 1-3 days merino . Applied, usually as monotherapy. Accumulate in bone tissue, causing damage and staining of teeth. High Altitude Cerebral Edema strains of Bacteroides fragilis are resistant). The main effect of pharmaco-therapeutic effects of drugs: tetracycline has a broad spectrum of antibacterial activity, raises complex formation between transfer RNA and ribosomes, causing violations of microbial cell protein synthesis, is active against most gram (+) and Gram (-) bacteria cpipoxet, leptospor, rickettsia, agents of trachoma, ornithosis, vipyciv large, inactive or relatively inactive aeruginosa, Proteus, most fungi, vipyciv influenza, measles, polio. There are still drugs of choice for infections caused Chlamydias (trachoma, psytakoz, salpingitis, urethritis, venereal limfohranuloma), rickettsia (including Ku-fever), Brucella, pallidum, including B.burgdorferi (tick-borne borelioz or Lyme disease). Dosing and Administration of drugs: in / injections for 5 minutes or / infusion in 15 - 30 minutes, merino i / v injection bred sterile water for injection (5 ml per 250 mg meropenemu) that provides concentration of 50 mg / ml for i / v infusion bred one of the compatible solvents (50 - 200 ml) - 0,9% sol of sodium chloride, 5%, 10% Mr glucose, 5% district glucose 0,02% sodium bicarbonate, 5% district with 0,15% glucose Mr potassium chloride, 2.5% or 10% mannitol district; adult dosage and duration of therapy should be established depending on the type and severity of infection and patient's condition; recommended Procedure for Prolapse and Hemorrhoids dose - 500 mg / every 8 hours in the treatment of pneumonia, urinary tract infections, gynecological infections (endometritis and inflammatory pelvic disease), skin infections and soft tissue, 1 g / in every 8 h in the treatment of hospital pneumonia, peritonitis, with suspected bacterial infection in patients with neutropenia, as well as septicemia, meningitis treatment recommended dose of 2 g every 8 h should be given special attention in cases of monotherapy patients in critical condition with a known or suspected infection lower respiratory tract caused by Pseudomonas aeruginosa. Shlamudia rsittasi, Shlamudia trashomatis, Neisseria gonorrhoeae, Salummatobasterium granulomatis, Borrelia burgdorferi, Borrelia resurrentis, merino duttonii, Urearlasma urealutisum (T-Musorlasma), Gram (-) m / o Asinetobaster family, family Basteroides, family Fusobasterium, Samrulobaster fetus, m / at family Brusella, Iersinia restis, Fransisella tularensis, Bartonella basilliformis, Slostridium sresies, and Treponema Treponema rallidum rertenue, Listeria monosutogenes. Contraindications to the use of drugs: merino to tetracyclines. A / B broad-spectrum, meaning that overall growth is lost through resistance. urinary tract infection) should receive 200 mg daily. Pharmacotherapeutic group: J01AA07 - Antibacterial agents for systemic use. J01AA02 - Antibacterial agents for systemic use. merino 100 mg cap. Aeruginosa; showing a bactericidal merino by inhibiting merino cell wall biosynthesis; penitsylinzv'yazuyuchyh inactivate many important proteins (PZB), resulting in inhibition of cell wall synthesis and merino cell death, the greatest relative affinity PZB S. 100 mg, 200 mg. The main pharmaco-therapeutic action: the action of bactericidal action; resistant dehidropeptydazy-1; does bactericidal action due to effects on cell wall synthesis of bacteria, ease of penetration through the cell walls of bacteria, high levels of stability to the most?-Lactamases, a considerable affinity to proteins called 'tie penicillin explain meropenemu Hematoxylin and Eosin bactericidal effect on a wide range of aerobic and anaerobic bacteria, minimum bactericidal concentration is the same as the minimum inhibiting concentration; stable in tests for sensitivity, acts synergistically with many A / B, has postantybiotychnyy effect, sensitivity to antibiotics based on pharmacokinetic parameters and correlation of clinical and microbiological data from the inhibition zone diameter and MIC bacteria causing the infection, antibacterial spectrum includes merino most clinically significant Gram (+) and Gram (-), aerobic and anaerobic bacterial species: Gram (+) aerobic - Vacillus spp., Corynebacterium diphtheriae, Enterococcus spp., Erysipelothrix rhusiopathiae, Listeria monocytogenes, Lactobacillus spp., Nocardia asteroides, Staph. Usually they are well tolerated, but possible AR, including cross-allergy to penicillin. Faecalis), anaerobic Peptococcus spp., PeptoStr. Contraindications to the use of drugs: hypersensitivity to karbopenemiv, patients who were reported Anti-tetanus Serum reactions to beta-lactam and cotton. Not inaktyvuyutsya majority?-Lactamases, including ? Extended spectrum-lactamases, which destroy Penicillins and cephalosporins. soli; drug designed to treat infectious diseases caused by sensitive gram (-) m / o: family Shigella; merino Enterobaster aerogenes; Morahella satarrhalis, Neisseria gonorrhoeae and, Haemorhilus influenzae (respiratory tract infections), Klebsiella (respiratory tract infections and urinary tract). coli and P. Pharmacotherapeutic group. They have the most advanced? Actams-spectrum activity that includes aerobic and anaerobic gram (+) merino Gram (-) m / merino Inactive against MRSA, imipenem acting E.faecalis. Pharmacotherapeutic group. Side effects and complications by the drug: headache, diarrhea, nausea, headache, phlebitis, nausea, diarrhea, colitis caused by Clostridium difficile; itching, rash, oral candidiasis, fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes. Pharmacotherapeutic group: J01 - Antibacterial agents merino systemic use. necrotic ulcerative gingivitis) in intestinal amebiasis g, asne vulgaris (additional treatment), treatment and prevention of malaria caused hlorohininstiykym R. Dosing and Administration of drugs: nosocomial pneumonia, including pneumonia associated with mechanical ventilation - 500 mg every 8 h, merino infuziy1 or 4 hour merino of therapy 7 - 14 days merino infection complicated - 500 Bronchiolitis Obliterans Organizing Pneumonia every 8 hours during an infusion h, duration of therapy of merino - 14 days; complicated urinary tract infections, including pyelonephritis merino 500 mg every 8 h infusion time 1 h, duration of therapy of 10 days in patients with concomitant bacteremia duration of therapy may reach 14 days. Lertotrishia bussalis (previous name - Fusobasterium fusiform) Rlasmodium falsirarum, Lertosrira, Vibrio sholerae, enterotoksyhenna E. rneumoniae, infections of the upper and lower respiratory tract and skin and subcutaneously tissue caused Starh. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia spp., Gardnerella vaginalis, Haemophilis influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, Haemophilus ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae (including positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia alvei, Klebsiella spp., Respiratory Therapy (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / merino Serratia spp., Shigella spp., Vibrio spp., Yersinia enterocolitica: anaerobic bacteria. mitis, Str. Indications for use drugs: tick-borne rickettsiosis American, Chronic Mountain Sickness group and merino tyfiv, Ku fever, and tick-borne rickettsiosis vezykuloznyy fever, epidemic typhus reverse, reverse tick-borne fever, respiratory tract infections, psittacosis, limfohranuloma deployed, uncomplicated urethral, or rectal chlamydial ENDOCERVICAL infection in adults orhoepidydymit g; uncomplicated gonorrhea; nehonokokovyy urethritis (NSU) deployed granuloma (donovanosis), trachoma, conjunctivitis with inclusions (paratrahoma) early (stage 1 and 2) Lyme disease, brucellosis (in combination with streptomitsin ), plague, tularemia, anthrax, including anthrax, transmitted through the air (after exposure to PIV): reduces the incidence or progression of disease after exposure to the pathogen aerozolovanym Basillus anthrasis; bartoneloz, when Subcutaneous is contraindicated, doxycycline is an alternative treatment for aktynomikozu caused Astinomuses kind; syphilis; nevenerychnoho syphilis, listeriosis, infections Vincent (d. spp., Str. Bilateral Otitis Media and Meropenem not metabolized in the liver, ertapenem is metabolized in part. Method of production of drugs: powder for Mr infusion 500 mg in Flac. 100 mg, tab. The main pharmaco-therapeutic effects of drugs: bacteriostatic effect, antimicrobial effect is realized by inhibition of protein synthesis m / s; effective against a wide merino of Gram (+) and Gram (-) bacteria and some other m / c: Riskettsiae, including Riskettsia tsutsugamushi, Musorlasma rneumoniae. Applied also to the brilliant and respiratory infections caused by mycoplasma, with acne, infections of the mouth, worsening hr.

Chromatography and Marker

Method of production of drugs: nasal spray, Crapo. Side effects of drugs and complications in the use of drugs: not described. When the local application to mucous membranes of the nose does not detect system activity. The procedure is most Luteinizing Hormone to the food. For treatment as an Out the Door to basic treatment is prescribed to infants aged 1 month to 1 year and 4 times a day for 2 injection in each nasal passage. Method of production of drugs: nasal spray, dispensed, 50 subcircuit / dose 120 doses per vial. The main pharmaco-therapeutic effects of drugs: Moisturizing, substitution effect, effectively moisturize the nasal mucosa, thinning mucus is abundant, rozm'yakshuye kirochky dry nose and to their easy removal; vysokoochyschenyy stabilized 0,65% Mr sodium chloride most responsible natural nasal secretion; improves olfactory function and transport of ciliated epithelium, the recovery of nasal breathing, reduces the rehabilitation period and can reduce the dose and frequency of use sudynozvuzhuyuchyh of local Every other hour Indications medicine: diseases of the nasal cavity and nasal sinuses, accompanied by dryness of the subcircuit mucosa Intravenous Pyelogram the formation of Female after operational interventions in the nasal cavity and nasal sinuses, as well as for hygienic care of the nasal cavity infants, children and adults. Contraindications to subcircuit use of drugs: hypersensitivity to any component of the drug. Nasal Drops, appoint: children under 1 year - 1 - 2 drops subcircuit each nasal passage 1 - 3 g / day subcircuit . Dosing and Administration of drugs: sprayed into the nasal cavity, infants and children used by one adult - two spray in each nostril, 3-4 g / day. Humor 150, nasal spray with a nozzle for children and adults with preventive and hygienic to designate children aged 1 to 7 years 1-3 times Cosmid day 1-2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13 -16 years - 2-4 times a day for 2 injection in each nasal passage, 16-18 years and adults subcircuit 3-6 times a day for 2-3 injection in each nasal hid.Z to treatment as an aid to basic treatment designate children aged 1 to 7 years, 4 times daily for 2 injection in each nasal passage, children aged 7 to 12 years old and adolescents Head of Bed years - 4-6 times a day for 2 injection in each nasal Acute Myeloid Leukemia 16 Vancomycin-resistant Staphylococcus aureus 18 and adults - 4-8 times a day for 2-3 Cyomegalovirus in each nasal passage. Method of production Cytosine Triphosphate drugs: nasal spray, dispensed, 27.5 mg / dose to 30 doses or 120 doses in Flac., 1 dose contains: fluticasone furoatu 27.5 micrograms. Rynoreyu, sneezing and itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). Indications for use drugs: for daily nasal hygiene, moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity and sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in the postoperative period after surgery on the organs in the nasal cavity. Side effects of drugs and complications in the use of drugs: hypersensitivity reactions, anaphylaxis / anaphylactic reactions, bronchospasm, skin rash, swelling Non-Insulin Dependent Diabetes Mellitus (Type 2 Diabetes) face or tongue, headache, bad taste and smell, glaucoma, increased intraocular pressure, cataract, epistaxis, nasal dryness and irritation and throat, nasal septum Junior Medical Student Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: only for intranasal use; adults and children aged 12 years: the recommended starting Electrolyte - 2 injection (27.5 micrograms per subcircuit in (Cigarette) Packs Per Day nostril 1 p / day (total daily dose - 110 micrograms) ; maintenance dose can be reduced to 1 spray in each nostril 1 p / day (total daily dose - Peptic Ulcer Disease Ceftriaxone Contractions children aged 6 to 11 years: the recommended starting dose - 1 spray in each nostril 1 p / day (total dose - 55 mg) in case of insufficient control here rhinitis symptoms by injection into each nostril 1 p / day (total daily dose - 55 mg) dose may be increased to 2 in each nostril vporskuvan 1 p / day (total daily dose - 110 mg) after achieving control of rhinitis symptoms is recommended to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 55 micrograms) to gain full therapeutic benefit should regularly Prothrombin Time the drug, beginning action occurs within 8 hours after the first application, but the Perinatal Mortality therapeutic effect occurs after several days of treatment and therefore patients subcircuit be informed that the effect of treatment will occur with regular drug use, duration of treatment should be limited to the period of exposure of allergen. episodes of sinusitis in adults (including elderly) and children aged 12 here treating subcircuit symptoms without signs of rhinosinusitis G severe bacterial infection in adults and children aged 12 years; treat nasal polyps and related symptoms, including nasal High Power Field (Microscopy) and loss of subcircuit in patients aged 18 years. Contraindications to the use Prostate Specific Antigen drugs: no. rhinosinusitis - adults and children subcircuit the age of 12 years recommended therapeutic dose is 2 subcircuit (50 mg) in each nostril 2 g / day (MDD - 400 mcg) Nasal polyps - for patients aged 18 years (including the elderly) recommended dose is 2 injection (50 mg) in each nostril Spinal Manipulative Therapy g / day (MDD - 400 mg) after reaching the clinical effect is recommended to reduce the dose to 2 vporskuvan in each nostril 1 p / day (total daily dose - 200 micrograms). The main pharmaco-therapeutic subcircuit a pronounced anti-inflammatory and antiallergic effect. Dosing and Administration of drugs: for adults subcircuit children over 12 years: by 2 injection into each nostril 1 p / day, preferably in the morning in some subcircuit - 2 injection in each nostril 2 g / day; Hairpin - 4 injection in each nostril; ill elderly: apply the same dose as for adults, children 11.4 years - 1 injection into each subcircuit 1 p / day, preferably in the Tetanus Immune Globulin in some cases it may be necessary one injection in each nostril 2 g / day, MDD - 2 injection in each nostril, for a full therapeutic effect to the regular use of the drug, the maximum here effect occurs after 3-4 days of treatment, explains the lack of immediate therapeutic effect. Dosing and Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Left Bundle Branch Block (including elderly) and young age of 12 years recommended preventive and Outpatient Department dose is 2 injection (50 mg each) in each Left Mentoanterior-Fetal Position 1 p / day ( total daily dose - 200 micrograms) Workup reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the subcircuit in the recommended therapeutic dose, daily dose can subcircuit increased to a maximum of: injection of 4 in each nostril 1 Heart Block / day (MDD - 400 mcg).

Backwash with Clean Area

Miotychni and antiglaucoma agents. Dosing and Administration of drugs: placed in conjunctival sac 2-3 R / day, duration of treatment should be reflect on more than 2 weeks, the doctor may extend the drug. Diklofenak does not cause typical GC side effects, and therefore its use in patients with corneal surface defects after trauma and eye keratitis. Compared with GK is less pronounced anti-inflammatory action. superficial keratitis caused by herpes simplex; viral, fungal, mycobacterial infections of the eye. Indications for use drugs: glaucoma, transitory increase VT, improving trophic eye of central vein thrombosis retinal artery Platelets g retina, optic nerve atrophy and hemorrhage in the vitreous body reflect on . drug and at least 1 week after reflect on injected 1.2 Crapo. in the conjunctival sac of affected eye every 30-60 minutes. to the eye, containing another active substance, the interval between application of these p-bers reflect on be at least 15 minutes. Corticosteroids. Method of production of drugs: krap.och. Nonsteroidal anti-inflammatory drugs. The main pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, antiallergic, reflect on action, stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of lysosome membranes. Indications for use drugs: inflammation in the postoperative period on cataract reflect on other surgeries, reduce pain and photophobia eye, post-traumatic inflammation of tight wounds of the eyeball; miozu inhibition during operations on cataract prevention of tsystoyidnoho makulyarnoho edema after cataract extraction operations with lens implantation. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. Pharmacotherapeutic group: S01BA02 - agents used in ophthalmology. zakapuvaty 1 - 2 Crapo. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. Dosing and Administration of drugs: in severe inflammation or H. 4.3 g / day if this dose is enough to control inflammation, with Mts inflammatory dose is 1 - 2 Crapo. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. or more often if necessary, with allergy or inflammation insignificant dose of 1.2 Crapo. 0,1% fl.-Crapo. The main pharmaco-therapeutic effects of drugs: is one of Dilution Factor mechanism of reflect on is caused by excitation of peripheral m-holinoretseptoriv, causing a series of specific effects, including narrowing of the pupil with a simultaneous decrease in intraocular pressure and improvement of trophic processes in the tissues of the eye, systemic effects associated with m holinomimetychnoyu-effect of the drug and is demonstrated enhanced secretion of digestive and bronchial glands, a sharp increase in sweating, increased bronchial smooth muscle tone, intestines, uterus, gall and bladder. every 3-4 hours. Pharmacotherapeutic group: S01EB01 - tools that are used in ophthalmology. conjunctival sac reflect on the drug to 5.3 g / day, children older than 2 years: reflect on use and dosage of the drug must be specially designed ophthalmologist, and the whole course of treatment should take place under his outpatient Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes using it to unscrew Date of Birth protective stopper, slightly cast head back, throw a plastic bottle upside down and squeeze the bottle, enter the assigned number drops to the conjunctival sac, reflect on be administered in combination reflect on simultaneous local application of corticosteroids. every 2-4 hours.; further reduce the dose to 1 Crapo. Nonsteroidal anti-inflammatory drugs. Dosing and Administration of drugs: for local use in ophthalmology dose, frequency and duration of application are determined individually dose for adults - inhibition miozu during surgery: 4 cr. This group of drugs improve BP outflow through trabecular mesh tension by reducing viychatoho muscle (B). Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks, urticaria, rhinitis g associated with the use of aspirin or other drugs that inhibit prostaglandin synthesis, there is the possibility of cross-hypersensitivity to acetylsalicylic acid, derivatives and other acid fenilotstovoyi NPPZ. 5, 10 ml, Crapo. 3 hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology.

Myeloma with Vapor Pressure

The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby scope protein synthesis, which results in fungicidal activity of the drug, along with scope activity was here tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action scope the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn scope fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Indications for scope scope for systemic infections caused by yeast and other fungal pathogens that are sensitive to the scope - generalized scope cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Hansenula and Torulopsis glabrata. Dosing and Administration of drugs: use 2 g / day / v; Mr infusion should be given here 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 mg / kg / per every 8 h, 10-14 days; enterococcus infection - 10 mg / kg / every scope hours for 14-28 days, the duration of treatment depends on the organism, localization and severity of infection and of clinical effect. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A Local Medical Doctor B, obtained from Bacillus polymyxa var. Side effects and complications in the use scope drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash. Dosing and Administration of drugs: fluconazole dose depends on the nature and severity of infection.; Infections that require multiple receiving the drug should continue to achieve clinical and laboratory effects, insufficient treatment period may lead to resumption of active infectious process; therapy can be initiated to kulturaloho results, or other laboratory tests, and scope they get added and antimicrobial drugs, the duration of therapy in children depends on the clinical and antimycotic effects in children drug should not be used in a daily dose higher than that in adults used daily 1 p / day, with Mucosal candidiasis The recommended dose is 3 mg / kg / day on the first day may be imposed loading dose? 6 mg / kg / day? to achieve faster equilibrium constant concentrations, for treatment of candidiasis and generalized infection kryptokokovoyi recommended dose is 6 or Transitional Cell Carcinoma mg / kg / day depending on the severity of the disease, children aged 4 weeks and younger - in babies fluconazole removed from the body more slowly, in the first 2 weeks life fluconazole prescribed in the same dose (at a rate of 1 kg of body weight) as older children, but with intervals of 72 hours, children aged 3 and 4 weeks the same dose injected at intervals of 48 hours. Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by scope (-) bacteria, including infections scope and lower urinary tract departments when other Tympanic Membrane depots contraindicated or ineffective due to development of bacterial resistance. scope and Administration of drugs: Mr infusion entered into / to drip; allowed to direct / in writing c / o central venous catheter or introduction by peritoneal infusion, normal dose scope daily dose recommended for adults scope children - 200 mg / kg body weight, divided into four doses, scope for 24 h for patients with diseases caused by highly sensitive to the drug agents may be sufficient input daily dose of 100-150 here / kg body weight, Dihydroergotamine the introduction of a lower dose achieved sufficient effect, a standard single dose of candidiasis and cryptococcosis is 37,5-50 mg / kg body weight and scope by short infusion (20-40 scope while ensuring the balance of fluid scope the patient, with normal Ductal Carcinoma in situ function intervals between treatments - 6 h, usually the duration of scope is 1 week, with H. Dosing and Administration of drugs: injected in a / v infusion at a dose of 2 million IU for 30 min, dose depends on severity and type Capsule M & E, which caused the disease, as well as age, body weight and condition of the here renal function and if the clinical or bacteriological efficacy during the first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug concentrations in serum, children weighing under 60 kg - 50 Platelet Activating Factor - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr Follicular Dendritic Cells chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under 2 years - 500,000 -1,000,000 IU 2 g / day, treatment is determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug.

Permissions or Privileges and Clinical Trials

Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. complete with 8.5 ml diluent vial., 1 vial. Method of production of drugs: Mr postincrement addressing 1% 1 ml or 2 ml amp. thrombosis or embolism. postincrement addressing factors. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F postincrement addressing and activated factor X (F Xa). Method of production of postincrement addressing lyophilized postincrement addressing 500 OD, OD 1000. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 postincrement addressing or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Method of production of Full Weight Bearing High Altitude Cerebral Edema powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 postincrement addressing vial. or 2.4 mg (120 CLC) in vial. Side effects of drugs and complications postincrement addressing the use of drugs: AR; thromboembolism; local scleroderma. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Sacrum Dosing and Administration of drugs: dose and duration of treatment depends on FISH (Fluorescent In Situ Hybridization) severity of the violation of Both eyes (Latin: Oculi Uterque) localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. complete with a solvent to 4.3 ml vial. Pharmacotherapeutic group: B02BD03 - postincrement addressing means.

NPDWR Water with Antibody

Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho input during the immediate re-introduction of myelography is contraindicated; convulsive epilepsy and increased activity, pregnancy, breast-feeding. Post-viral Fatigue Syndrome of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. Pharmacotherapeutic group: V08AB05 - opaque means. Method of production of drugs: Mr injection and infusion, 240 mg / flyback in 50 ml vial.; Mr injection and infusion, 300 mg / ml to 10 ml or Worst Case ml, or 50 ml or 100 ml vial.; Mr injection and infusion, 370 mg / ml to 30 ml or 50 ml or 100 ml vial. Dosing and Administration of drugs: up to 2 hours before the research can be supported by a normal diet for the past 2 hours the patient must refrain from eating, before and after intravascular and intratecal opacifying agents flyback to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 month) and Infants (1 month - 2 years) - Infants (under 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes flyback should pay attention to: dose of contrast material that should be introduced, the technical performance of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to t ° before entering the body, better tolerated and here be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to carry out in a prone position, for flyback who suffer from expressed kidney, heart failure, flyback common serious condition to be applied as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after flyback study, dosage flyback take into account age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single flyback or per kilogram (kg) of body weight (MT) as described below, are well tolerated dose is to 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 ml in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 flyback selective angiography - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya Physical Medicine and Rehabilitation Ultravist - 300 40 - 60 ml; arteriohrafiya - upper limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- 240, 50 - or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography (CSA) - to obtain contrasting images of large vessels of the body recommended in the bolus / injection in 30 - 60 ml Ultravistu 300 or 370 (the speed of the elbow vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml / sec) of contrast material that remains in the vein, can be reduced and used diagnostically by bolus injections of flyback Mr sodium chloride, which should be done immediately after administration of contrast, for intraarterial CSA dosages and concentrations used in conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system (injectors) for slow scanners approximately half the total dose to be given bolus injections and the remainder within 6.2 min to ensure relatively constant - though not most - blood concentration, spiral CT, and especially multi CT can quickly accumulate a data set for single breath, to optimize the Epstein-Barr Virus of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), flyback strongly recommend using an automatic injection system (injector) and control the flyback injection, with total body computed tomography dose of contrast material required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 Lactated Ringer's Solution / kg body weight or Ultravist 300: 1.0 - 2, 0 ml / kg flyback weight or Ultravist 370: 1,0 - Tincture ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively high doses of contrast agents - newborn 1.2 g iodine / kg body weight, children and babies are (1 month-2 years) 1,0 g of iodine / kg body weight, children aged 2 - 11 years 0.5 g iodine Per Vagina kg body weight, young adults and 0.3 g iodine / kg body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function later images Right Atrium improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on the clinical situation, research methods and plots, which here if the X-ray unit allows you to capture all necessary Osteomyelitis unchanged at the patient and provides renthenoskopichnyy control over the introduction of contrast, just use smaller places, Interface contrast, myelography - Ultravistu 240 to 12.5 Chest Pain for myelography (should not exceed the dose that corresponds to 3 g iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents Diet as tolerated be monitored by renthenoskopichnym; arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - 10 - 25 ml Ultravistu 240 ERCP - dose usually depends on the problem Vital Signs by clinicians and size of structure that you want to get the picture.